Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Table 3 Percentage of patients with improved, stable, or worsened QLQ-BR23 scores from baseline at cycle 6

QLQ-BR23 Quality-of-Life Questionnaire for Breast Cancer, SE side effect
^aFor global health status and functional scales, improved scores are defined as increases from baseline ≥10; worsened is defined as decreases from baseline ≥10
^bFor symptom scales/items, Improved scores are defined as decreases from baseline ≥10; worsened is defined as increases from baseline ≥10

ISSN: 1471-2407